Factor VIII trafficking to CD4(+) T cells shapes its immunogenicity and requires several types of antigen-presenting cells

Despite >80 years of clinical experience with coagulation factor VIII (FVIII) inhibitors, surprisingly little is known about the in vivo mechanism of this most serious complication of replacement therapy for hemophilia A. These neutralizing antidrug alloantibodies arise in ∼30% of patients. Inhib...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaczmarek, Radoslaw, Piñeros, Annie R., Patterson, Paige E., Bertolini, Thais B., Perrin, George Q., Sherman, Alexandra, Born, Jameson, Arisa, Sreevani, Arvin, Matthew C., Kamocka, Malgorzata M., Martinez, Michelle M., Dunn, Kenneth W., Quinn, Sean M., Morris, Johnathan J., Wilhelm, Amelia R., Kaisho, Tsuneyasu, Munoz-Melero, Maite, Biswas, Moanaro, Kaplan, Mark H., Linnemann, Amelia K., George, Lindsey A., Camire, Rodney M., Herzog, Roland W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2023
Materias:
Thrombosis and Hemostasis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10375270/
https://www.ncbi.nlm.nih.gov/pubmed/37192286
http://dx.doi.org/10.1182/blood.2022018937

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10375270/
https://www.ncbi.nlm.nih.gov/pubmed/37192286
http://dx.doi.org/10.1182/blood.2022018937

Ejemplares similares